Antitrust regulators from the European Union are investigating a suspected agreement between Johnson & Johnson and Novartis to delay the sale of a generic painkiller in the Netherlands.
The European Commission has expressed a concern that contractual agreements may have blocked the sale of generic fentanyl patches, constituting a breach of EU antitrust rules.
Go deeper with GlobalData
EU Competition Commissioner Joaquin Almunia said that paying a competitor to stay out of the market is a restriction of competition that the Commission will not tolerate.
Stefan Gijssels, a spokesman for Johnson & Johnson’s European arm Janssen, said that the company was cooperating fully.
"The investigation focuses on contractual arrangements with Hexal/Sandoz concerning fentanyl patches in the Netherlands in the period 2005-2006," he added.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
